Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Loibl S, et al. Among authors: tjulandin s. Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13. Ann Oncol. 2024. PMID: 38101773 No abstract available.
Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.
Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, Ryabaya O, Byakhov M, Tjulandin S. Tsimafeyeu I, et al. Among authors: tjulandin s. Eur J Cancer. 2016 Jul;61:20-8. doi: 10.1016/j.ejca.2016.03.068. Epub 2016 Apr 29. Eur J Cancer. 2016. PMID: 27136102
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A, Harrison D, Yin W, Stepanova E, Kochenkov D, Solomko E, Peretolchina N, Daeyaert F, Joos JB, Van Aken K, Byakhov M, Gavrilova E, Tjulandin S, Tsimafeyeu I. Tyulyandina A, et al. Among authors: tjulandin s. Invest New Drugs. 2017 Apr;35(2):127-133. doi: 10.1007/s10637-016-0404-1. Epub 2016 Nov 3. Invest New Drugs. 2017. PMID: 27812884
Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28].
Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, Ryabaya O, Byakhov M, Tjulandin S. Tsimafeyeu I, et al. Among authors: tjulandin s. Eur J Cancer. 2017 Jan;70:156. doi: 10.1016/j.ejca.2016.11.001. Epub 2016 Dec 3. Eur J Cancer. 2017. PMID: 27919550 No abstract available.
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.
Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, Hudoyo A, He Y, Zhang YP, Wang MZ, Liu CY, Ratcliffe M, McCormack R, Reck M. Han B, et al. Among authors: tjulandin s. Lung Cancer. 2017 Nov;113:37-44. doi: 10.1016/j.lungcan.2017.08.021. Epub 2017 Sep 1. Lung Cancer. 2017. PMID: 29110846
Bridging the Gap in Global Advanced Radiation Oncology Training: Impact of a Web-Based Open-Access Interactive Three-Dimensional Contouring Atlas on Radiation Oncologist Practice in Russia.
McClelland S 3rd, Chernykh M, Dengina N, Gillespie EF, Likhacheva A, Usychkin S, Pankratov A, Kharitonova E, Egorova Y, Tsimafeyeu I, Tjulandin S, Thomas CR Jr, Mitin T. McClelland S 3rd, et al. Among authors: tjulandin s. J Cancer Educ. 2019 Oct;34(5):871-873. doi: 10.1007/s13187-018-1388-7. J Cancer Educ. 2019. PMID: 29938298
133 results